Community-Acquired Pneumonia—Back to Basics

  • Marc J.M. Bonten
  • Jan Jelrik Oosterheert


Lower respiratory tract infections are among the most common infectious diseases worldwide and are caused by the inflammation and consolidation of lung tissue due to an infectious agent.1 The clinical criteria for the diagnosis include chest pain, cough, auscultatory findings such as rales or evidence of pulmonary consolidation, fever, or leukocytosis.


Intensive Care Unit Admission Influenza Vaccination Lower Respiratory Tract Infection Pneumococcal Pneumonia Severe Acute Respiratory Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501–513.PubMedGoogle Scholar
  2. 2.
    Chow AW, Hall CB, Klein JO, et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992;15:s62–s88.PubMedGoogle Scholar
  3. 3.
    Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994;96:313–320.PubMedGoogle Scholar
  4. 4.
    Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986;146:2179–2185.PubMedGoogle Scholar
  5. 5.
    Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502–508.PubMedGoogle Scholar
  6. 6.
    Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994;105:1487–1495.Google Scholar
  7. 7.
    Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312–318.PubMedGoogle Scholar
  8. 8.
    Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189–193.PubMedGoogle Scholar
  9. 9.
    Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–186.PubMedGoogle Scholar
  10. 10.
    Pneumonia and influenza death rates—United States, 1979–1994. MMWR 1995;44:535–537.Google Scholar
  11. 11.
    Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA 2005;294:2712–2719.PubMedGoogle Scholar
  12. 12.
    Oosterheert JJ, Bonten MJ, Hak E, et al. [The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it]. Ned Tijdschr Geneeskd 2004;148:1765–1769.PubMedGoogle Scholar
  13. 13.
    Guest JF, Morris A. Community-acquired pneumonia: The annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530–1534.PubMedGoogle Scholar
  14. 14.
    Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709–1718.PubMedGoogle Scholar
  15. 15.
    Lave JR, Lin CJ, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189–197.Google Scholar
  16. 16.
    Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31–40.PubMedGoogle Scholar
  17. 17.
    Ruiz M, Ewig S, Marcos MA, et al. Etiology of community acquired pneumonia: Impact of age, comorbidity and severity. Am J Respir Crit Care Med 1999;160:397–405.PubMedGoogle Scholar
  18. 18.
    Lim WS, Macfarlane JT, Boswell TCJ, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines. Thorax 2001;56:296–301.PubMedGoogle Scholar
  19. 19.
    Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: Influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001;184:268–277.PubMedGoogle Scholar
  20. 20.
    Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 1996;51:179–184.PubMedGoogle Scholar
  21. 21.
    Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: Etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000;118:1344–1354.PubMedGoogle Scholar
  22. 22.
    Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746–1754.PubMedGoogle Scholar
  23. 23.
    Bohte R, Furth R van, Broek PJ van den. Aetiology of community-acquired pneumonia; a prospective study among adults requiring admission to hospital. Thorax 1995;50:543–547.PubMedGoogle Scholar
  24. 24.
    Vegelin AL, Bissumbhar P, Joore JCA, Lammers JWJ, Hoepelman IM. Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 1999;55:110–117.PubMedGoogle Scholar
  25. 25.
    van Elden LJ, van Loon AM, van Alphen F, et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis 2004;189:652–657.PubMedGoogle Scholar
  26. 26.
    Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis 2002;185:1338–1341.PubMedGoogle Scholar
  27. 27.
    Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–1976.PubMedGoogle Scholar
  28. 28.
    Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–1966.PubMedGoogle Scholar
  29. 29.
    Woo PC, Lau SK, Tsoi HW, et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 2004;363:841–845.PubMedGoogle Scholar
  30. 30.
    Vabret A, Mourez T, Gouarin S, Petitjean J, Freymuth F. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin Infect Dis 2003;36:985–989.PubMedGoogle Scholar
  31. 31.
    Hoek vdL, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004;10:368–373.PubMedGoogle Scholar
  32. 32.
    Kahn JS. Human metapneumovirus: A newly emerging respiratory pathogen. Curr Opin Infect Dis 2003;16:255–258.PubMedGoogle Scholar
  33. 33.
    van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–724.PubMedGoogle Scholar
  34. 34.
    Farr BM, Kaiser DL, Harrison BDW, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989;44:1031–1035.PubMedGoogle Scholar
  35. 35.
    Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community-acquired legionnaires’ disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984;39:28–33.PubMedGoogle Scholar
  36. 36.
    Woodhead MA, Macfarlane JT, American Thoracic Society. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987;81:133–139.PubMedGoogle Scholar
  37. 37.
    Bohte R, Hermans J, van den Broek PJ. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:201–205.PubMedGoogle Scholar
  38. 38.
    Hopstaken RM, Muris JW, Knottnerus JA, et al. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003;53:358–364.PubMedGoogle Scholar
  39. 39.
    Hopstaken RM, Stobberingh EE, Knottnerus JA, et al. Clinical items not helpful in differentiating viral from bacterial lower respiratory tract infections in general practice. J Clin Epidemiol 2005;58:175–183.PubMedGoogle Scholar
  40. 40.
    Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004;113:701–707.PubMedGoogle Scholar
  41. 41.
    Toikka P, Irjala K, Juven T, et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000;19:598–602.PubMedGoogle Scholar
  42. 42.
    Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Clusterrandomised, single-blinded intervention trial. Lancet 2004;363:600–607.PubMedGoogle Scholar
  43. 43.
    Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278–1281.PubMedGoogle Scholar
  44. 44.
    Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. Chest 2002;121:1486–1492.PubMedGoogle Scholar
  45. 45.
    Reed WW, Byrd GS, Gates RH Jr, et al. Sputum Gram’s stain in community acquired pneumonia: A meta analysis. West J Med 1996;165:197.PubMedGoogle Scholar
  46. 46.
    Smith PR. What diagnostic tests are needed for community-acquired pneumonia. Med Clin North Am 2001;85:1381–1396.PubMedGoogle Scholar
  47. 47.
    Corbo J, Friedman B, Bijur P, Gallagher EJ. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004;21:446–448.PubMedGoogle Scholar
  48. 48.
    van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241–249.PubMedGoogle Scholar
  49. 49.
    van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: A prospective randomised study. Thorax 2005;60:672–678.PubMedGoogle Scholar
  50. 50.
    American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia. Am J Crit Care Med 2001;163:1730–1754.Google Scholar
  51. 51.
    Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347–382.PubMedGoogle Scholar
  52. 52.
    Skov Sorensen UB, Henrichsen J. Cross-reactions between pneumococci and other streptococci due to C polysaccaride and F antigen. J Clin Microbiol 1987;25:1854–1859.Google Scholar
  53. 53.
    Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. Clin Microbiol 2001;39:3495–3498.Google Scholar
  54. 54.
    Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001;32:824–825.PubMedGoogle Scholar
  55. 55.
    Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in the Netherlands. Clin Microbiol 2002;40:3232–3236.Google Scholar
  56. 56.
    Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires’ disease at a Dutch flower show: Prognostic factors and impact of therapy. Emerg Infect Dis 2002;8:1448–1454.PubMedGoogle Scholar
  57. 57.
    Elden LJ van, Nijhuis M, Schipper P, Schuurman R, Loon AM van. Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. Clin Microbiol 2001;39:196–200.Google Scholar
  58. 58.
    Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005;41:1438–1444.PubMedGoogle Scholar
  59. 59.
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–10.PubMedGoogle Scholar
  60. 60.
    Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002;2:404–415.PubMedGoogle Scholar
  61. 61.
    Davidson R, Cavalcanti R, Brunton J, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747–749.PubMedGoogle Scholar
  62. 62.
    Low DE. Quinolone resistance among pneumococci: Therapeutic and diagnostic implications. Clin Infect Dis 2004;38 Suppl 4:S357-S362.Google Scholar
  63. 63.
    Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425–2426.PubMedGoogle Scholar
  64. 64.
    Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445–1453.PubMedGoogle Scholar
  65. 65.
    Bradley SF. Staphylococcus aureus pneumonia: Emergence of MRSA in the community. Semin Respir Crit Care Med 2005;26:643–649.PubMedGoogle Scholar
  66. 66.
    Neuhaus T, Ewig S. Defining severe community-acquired pneumonia. Med Clin North Am 2001;85:1413–1425.PubMedGoogle Scholar
  67. 67.
    BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56 Suppl 4:IV1–64.Google Scholar
  68. 68.
    Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102–1108.PubMedGoogle Scholar
  69. 69.
    Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997;336:243–250.PubMedGoogle Scholar
  70. 70.
    Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003;58:377–382.PubMedGoogle Scholar
  71. 71.
    Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a betalactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389–395.PubMedGoogle Scholar
  72. 72.
    Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000;22:872–878.PubMedGoogle Scholar
  73. 73.
    Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals. Ann Pharmacother 2000;34:446–452.PubMedGoogle Scholar
  74. 74.
    Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562–2572.PubMedGoogle Scholar
  75. 75.
    Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states. Chest 2001;119:1420–1426.PubMedGoogle Scholar
  76. 76.
    Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: A 20-year longitudinal study, 1978–1997. Am J Med 1999;107:34S-43S.PubMedGoogle Scholar
  77. 77.
    Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pnuemonia. Arch Intern Med 1999;159:2576–2580.PubMedGoogle Scholar
  78. 78.
    Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe pneumococcal pneumonia. Arch Intern Med 2001;161:1837–1842.PubMedGoogle Scholar
  79. 79.
    Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003;289:885–888.PubMedGoogle Scholar
  80. 80.
    McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003;9:424–430.PubMedGoogle Scholar
  81. 81.
    Oosterheert JJ, Bonten MJ, Schneider MM, Hoepelman IM. Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in the Netherlands. Clin Microbiol Infect 2005;11:992–998.PubMedGoogle Scholar
  82. 82.
    File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965–1972.PubMedGoogle Scholar
  83. 83.
    Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697–1705.PubMedGoogle Scholar
  84. 84.
    Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456.PubMedGoogle Scholar
  85. 85.
    Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: Systematic review of randomized controlled trials. Arch Intern Med 2005;165:1992–2000.PubMedGoogle Scholar
  86. 86.
    Matute AJ, Schurink CA, Hoepelman IM. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila? J Antimicrob Chemother 2000;45:930–931.PubMedGoogle Scholar
  87. 87.
    El Moussaoui R., Prins J, et al. Three versus eight days of amoxicillin in mild to moderate-severe CAP. Program and Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy 2004, Abstract L-661. Washington, DC.Google Scholar
  88. 88.
    Rhew DC, Weingarten SR. Achieving a safe and early discharge for patients with community-acquired pneumonia. Med Clin North Am 2001;85:1427–1440.PubMedGoogle Scholar
  89. 89.
    Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273–1276.PubMedGoogle Scholar
  90. 90.
    Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449–2454.PubMedGoogle Scholar
  91. 91.
    Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965–971.PubMedGoogle Scholar
  92. 92.
    Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965–971.PubMedGoogle Scholar
  93. 93.
    Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: A randomized controlled trial. Am J Med 2001;111:367–374.PubMedGoogle Scholar
  94. 94.
    Oosterheert JJ, Bonten MJ, Schneder MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in servere community acquired pneumonia: multicentre randomised trial. BMJ. 2006 Dec 9;333(7580):1193PubMedGoogle Scholar
  95. 95.
    Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333–1339.PubMedGoogle Scholar
  96. 96.
    Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399–403.PubMedGoogle Scholar
  97. 97.
    Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34:1613–1620.PubMedGoogle Scholar
  98. 98.
    Gross PA. Vaccines for pneumonia and new antiviral therapies. Med Clin North Am 2001;85:1531–1544.PubMedGoogle Scholar
  99. 99.
    Hak E, Grobbee DE, van Essen GA, Buskens E, Verheij TJ. Pneumococcal vaccination of the elderly: Do we need another trial? Arch Intern Med 2000;160:1698–1699.PubMedGoogle Scholar
  100. 100.
    Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437–2442.PubMedGoogle Scholar
  101. 101.
    Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: A prospective study. Lancet 2001;357:1008–1011.PubMedGoogle Scholar
  102. 102.
    Ahmed F, Singleton JA, Franks AL. Clinical practice. Influenza vaccination for healthy young adults. N Engl J Med 2001;345:1543–1547.PubMedGoogle Scholar
  103. 103.
    Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: Even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001;33:2079.Google Scholar
  104. 104.
    Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 western European countries. Clin Infect Dis 2001;31:444–450.Google Scholar
  105. 105.
    Hak E, Hoes A, Verheij TJ. Influenza vaccination. Who needs them and when? Drugs 2002;62:2413–2420.PubMedGoogle Scholar
  106. 106.
    Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: The PRISMA study. Arch Intern Med 2005;165:274–280.PubMedGoogle Scholar
  107. 107.
    Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518–527.PubMedGoogle Scholar
  108. 108.
    Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957–1030.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Marc J.M. Bonten
    • 1
  • Jan Jelrik Oosterheert
    • 1
  1. 1.Department of Internal Medicine and Infectious DiseasesUniversity Medical CentreUtrechtThe Netherlands

Personalised recommendations